Limits...
Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.

Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, Jia B - PLoS ONE (2014)

Bottom Line: Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images.Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign.In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, the 1st Affiliated Hospital of Fujian Medical University, Fuzhou, China.

ABSTRACT

Purpose: 99mTc-3PRGD2, a promising tracer targeting integrin receptor, may serve as a novel tumor-specific agent for single photon emission computed tomography (SPECT). A multi-center study was prospectively designed to evaluate the diagnostic accuracy of 99mTc-3PRGD2 imaging for bone metastasis in patients with lung cancer in comparison with the conventional 99mTc-MDP bone scan.

Methods: The patients underwent whole-body scan and chest tomography successively at both 1 h and 4 h after intravenous injection of 11.1 MBq/Kg 99mTc-3PRGD2. 99mTc-MDP whole-body bone scan was routinely performed within 1 week for comparison. Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images. The final diagnosis was established based on the comprehensive assessment of all available data.

Results: A total of 44 patients (29 male, 59±10 years old) with suspected lung cancer were recruited from 4 centers. Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign. In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively. The corresponding diagnostic values for 99mTc-MDP bone scan were 87.6%, 60.9%, and 82.1%, respectively in the same patients. 99mTc-MDP bone scan had better contrast in most lesions, whereas the 99mTc-3PRGD2 imaging seemed to be more effective to exclude pseudo-positive lesions and detect bone metastases without osteogenesis.

Conclusion: 99mTc-3PRGD2 is a novel tumor-specific agent based on SPECT technology with a promising value in diagnosis of bone metastasis in patients with lung cancer.

Trial registration: ClinicalTrials.gov NCT01737112.

Show MeSH

Related in: MedlinePlus

Comparison of 99mTc-3PRGD2 SPECT, 99mTc-MDP bone scan (posterior), and CT scan in a 62 year-old woman with left upper lung adenocarcinoma (green arrow) and costal metastasis (red arrow).A: 99mTc -3PRGD2 WB(+), B: 99mTc -3PRGD2 SPECT (+), C: 99mTc -MDP bone scan (+), D: CT (+). WB: whole body.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4206469&req=5

pone-0111221-g001: Comparison of 99mTc-3PRGD2 SPECT, 99mTc-MDP bone scan (posterior), and CT scan in a 62 year-old woman with left upper lung adenocarcinoma (green arrow) and costal metastasis (red arrow).A: 99mTc -3PRGD2 WB(+), B: 99mTc -3PRGD2 SPECT (+), C: 99mTc -MDP bone scan (+), D: CT (+). WB: whole body.

Mentions: In the 44 recruited patients, 27 were found with bone lesions. According to the comprehensive assessment, 18 patients were diagnosed with bone metastasis and 9 with benign bone lesion (Fig. 1–4). In the lesion-based analysis of the 27 patients, 112 bone lesions were detected in total, among which 89 were diagnosed as bone metastasis and 23 were benign lesions. The diagnostic efficacy for the assessment of bone metastasis was compared among the 1-h and 4-h 99mTc-3PRGD2 imaging and the 99mTc-MDP whole-body scan (Table 3).


Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.

Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, Jia B - PLoS ONE (2014)

Comparison of 99mTc-3PRGD2 SPECT, 99mTc-MDP bone scan (posterior), and CT scan in a 62 year-old woman with left upper lung adenocarcinoma (green arrow) and costal metastasis (red arrow).A: 99mTc -3PRGD2 WB(+), B: 99mTc -3PRGD2 SPECT (+), C: 99mTc -MDP bone scan (+), D: CT (+). WB: whole body.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4206469&req=5

pone-0111221-g001: Comparison of 99mTc-3PRGD2 SPECT, 99mTc-MDP bone scan (posterior), and CT scan in a 62 year-old woman with left upper lung adenocarcinoma (green arrow) and costal metastasis (red arrow).A: 99mTc -3PRGD2 WB(+), B: 99mTc -3PRGD2 SPECT (+), C: 99mTc -MDP bone scan (+), D: CT (+). WB: whole body.
Mentions: In the 44 recruited patients, 27 were found with bone lesions. According to the comprehensive assessment, 18 patients were diagnosed with bone metastasis and 9 with benign bone lesion (Fig. 1–4). In the lesion-based analysis of the 27 patients, 112 bone lesions were detected in total, among which 89 were diagnosed as bone metastasis and 23 were benign lesions. The diagnostic efficacy for the assessment of bone metastasis was compared among the 1-h and 4-h 99mTc-3PRGD2 imaging and the 99mTc-MDP whole-body scan (Table 3).

Bottom Line: Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images.Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign.In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, the 1st Affiliated Hospital of Fujian Medical University, Fuzhou, China.

ABSTRACT

Purpose: 99mTc-3PRGD2, a promising tracer targeting integrin receptor, may serve as a novel tumor-specific agent for single photon emission computed tomography (SPECT). A multi-center study was prospectively designed to evaluate the diagnostic accuracy of 99mTc-3PRGD2 imaging for bone metastasis in patients with lung cancer in comparison with the conventional 99mTc-MDP bone scan.

Methods: The patients underwent whole-body scan and chest tomography successively at both 1 h and 4 h after intravenous injection of 11.1 MBq/Kg 99mTc-3PRGD2. 99mTc-MDP whole-body bone scan was routinely performed within 1 week for comparison. Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images. The final diagnosis was established based on the comprehensive assessment of all available data.

Results: A total of 44 patients (29 male, 59±10 years old) with suspected lung cancer were recruited from 4 centers. Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign. In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively. The corresponding diagnostic values for 99mTc-MDP bone scan were 87.6%, 60.9%, and 82.1%, respectively in the same patients. 99mTc-MDP bone scan had better contrast in most lesions, whereas the 99mTc-3PRGD2 imaging seemed to be more effective to exclude pseudo-positive lesions and detect bone metastases without osteogenesis.

Conclusion: 99mTc-3PRGD2 is a novel tumor-specific agent based on SPECT technology with a promising value in diagnosis of bone metastasis in patients with lung cancer.

Trial registration: ClinicalTrials.gov NCT01737112.

Show MeSH
Related in: MedlinePlus